Therefore, compared with parent compound ZLDI-8, the activity and safety of compound NY-2 have both been improved, and NY-2 can take its place as a potential antitumor agent for NSCLC treatment, targeting the Notch1 and integrinβ1 signaling pathways. This evidence concerns the gene NOTCH1 and non-small cell lung carcinoma.